Androfen Calculations Off Target For Reasonable Interpretations Of Claim – ERSP
This article was originally published in The Tan Sheet
Androfen should discontinue claims its testosterone-boosting supplement can “reduce body fat by over 200%” because consumers can interpret it in a way that is not supported, ERSP says. The firm can continue to claim the fenugreek product enhances libido and promotes body fat loss.
You may also be interested in...
FDA to update Nutrition and Supplement Facts labels; Valeant over performs in Q4, 2013; “probiotic” alone is a health claim, ASA; Troxyphen claims need modification, ERSP; and more In Brief.
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.